title: Metabolism of xenobiotics by aldehyde oxidase.
abstract: Aldehyde oxidase (AO) is a cytosolic molybdoflavoprotein whose contribution to the metabolism and clearance of xenobiotics-containing heterocyclic rings has attracted increased interest in recent years. This unit details methods for identification and confirmation of AO as a metabolic pathway as well as a method for estimating clearance of compounds that are AO substrates.
authors: Pfizer Global Research and Development, LaJolla Laboratories, San Diego.
authors: Deepak
authors: D
authors: Dalvie
authors: Pfizer Global Research and Development, LaJolla Laboratories, San Diego.
authors: Michael
authors: M
authors: Zientek
mesh_terms: D042931:Aldehyde Oxidase / Q000378:metabolism*; D001681:Biological Assay / Q000379:methods*; D001711:Biotransformation; D002851:Chromatography, High Pressure Liquid; D056148:Chromatography, Reverse-Phase; D005260:Female; D006146:Guanidines / Q000378:metabolism*; D006801:Humans; D008297:Male; D008862:Microsomes, Liver / Q000201:enzymology; D011720:Pyrazoles / Q000378:metabolism*; D021241:Spectrometry, Mass, Electrospray Ionization; D013379:Substrate Specificity; D053719:Tandem Mass Spectrometry; D057188:Workflow; D015262:Xenobiotics / Q000378:metabolism*
chemical_list: D006146:Guanidines; D011720:Pyrazoles; D015262:Xenobiotics; C424422:zoniporide; D042931:Aldehyde Oxidase
keywords: aldehyde oxidase (AO); heteroaromatic rings; liver S9 fraction; liver cytosol
references: Akabane, T. , Gerst, N. , Masters, J.N. , and Tamura, K. 2012a. A quantitative approach to hepatic clearance prediction of metabolism by aldehyde oxidase using custom pooled hepatocytes. Xenobiotica 42:863-871.
references: Akabane, T. , Gerst, N. , Naritomi, Y. , Masters, J.N. , and Tamura, K. 2012b. A practical and direct comparison of intrinsic metabolic clearance of several non-CYP enzyme substrates in freshly isolated and cryopreserved hepatocytes. Drug Metab. Pharmacokinet. 27:181-191.
references: Barr, J.T. , Choughule, K. , and Jones, J.P. 2014. Enzyme kinetics, inhibition, and regioselectivity of aldehyde oxidase. Methods Mol. Biol. 1113:167-186.
references: Choughule, K.V. , Barr, J.T. , and Jones, J.P. 2013. Evaluation of rhesus monkey and guinea pig hepatic cytosol fractions as models for human aldehyde oxidase. Drug Metab. Dispos. 41:1852-1858.
references: Dalvie, D. , Zhang, C. , Chen, W. , Smolarek, T. , Obach, R.S. , and Loi, C.M. 2010. Cross-species comparison of the metabolism and excretion of zoniporide: Contribution of aldehyde oxidase to interspecies differences. Drug Metab. Dispos. 38:641-654.
references: Garattini, E. and Terao, M. 2011. Increasing recognition of the importance of aldehyde oxidase in drug development and discovery. Drug. Metab. Rev. 43:374-386.
references: Garattini, E. and Terao, M. 2012. The role of aldehyde oxidase in drug metabolism. Expert Opin. Drug Metab. Toxicol.
references: Garattini, E. , Fratelli, M. , and Terao, M. 2008. Mammalian aldehyde oxidases: Genetics, evolution and biochemistry. Cell Mol. Life Sci. 65:1019-1048.
references: Garattini, E. , Fratelli, M. , and Terao, M. 2009. The mammalian aldehyde oxidase gene family. Hum. Genomics 4:119-130.
references: Garattini, E. , Mendel, R. , Romao, M.J. , Wright, R. , and Terao, M. 2003. Mammalian molybdo-flavoenzymes, an expanding family of proteins: Structure, genetics, regulation, function and pathophysiology. Biochem. J. 372:15-32.
references: Houston, J.B. and Galetin, A. 2008. Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr. Drug Metab. 9:940-951.
references: Hutzler, J.M. , Obach, R.S. , Dalvie, D. , and Zientek, M.A. 2013. Strategies for a comprehensive understanding of metabolism by aldehyde oxidase. Expert Opin. Drug Metab. Toxicol. 9:153-168.
references: Hutzler, J.M. , Yang, Y.S. , Brown, C. , Heyward, S. , and Moeller, T. 2014. Aldehyde oxidase activity in donor-matched fresh and cryopreserved human hepatocytes and assessment of variability in 75 donors. Drug Metab. Dispos. 42:1090-1097.
references: Hutzler, J.M. , Yang, Y.S. , Albaugh, D. , Fullenwider, C.L. , Schmenk, J. , and Fisher, M.B. 2012. Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. Drug Metab. Dispos. 40:267-275.
references: Johnson, C. , Stubley-Beedham, C. , and Stell, J.G. 1985. Hydralazine: A potent inhibitor of aldehyde oxidase activity in vitro and in vivo. Biochem. Pharmacol. 34:4251-4256.
references: Kitamura, S. , Sugihara, K. , and Ohta, S. 2006. Drug-metabolizing ability of molybdenum hydroxylases. Metab. Pharmacokinet. 21:83-98.
references: Mendel, R.R. 2009. Cell biology of molybdenum. BioFactors 35:429-434.
references: Obach, R.S. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. 27:1350-1359.
references: Obach, R.S. 2004. Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab. Dispos. 32:89-97.
references: Obach, R.S. , Huynh, P. , Allen, M.C. , and Beedham, C. 2004. Human liver aldehyde oxidase: Inhibition by 239 drugs. Br. J. Clin Pharmacol. 44:7-19.
references: Pryde, D.C. , Dalvie, D. , Hu, Q. , Jones, P. , Obach, R.S. , and Tran, T.D. 2010. Aldehyde oxidase: An enzyme of emerging importance in drug discovery. J. Med. Chem. 53:8441-8460.
references: Strelevitz, T.J. , Orozco, C.C. , and Obach, R.S. 2012. Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: Estimation of the contribution of aldehyde oxidase to metabolic clearance. Drug Metab. Dispos. 40:1441-1448.
references: Zientek, M. , Jiang, Y. , Youdim, K. , and Obach, R.S. 2010. In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab. Dispos. 38:1322-1327.